Conditions: Neoplasms
Keywords: solid tumor Axitinib Pharmacokinetics Phase 1
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: no

Brief summary:
This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Axitinib (AG-013736)
Intervention descriptions: intervention 1: Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.

Protocol document: